The independent source for health policy research, polling, and news.
181 - 200 of 474 Results
Private equity-backed Headlands Research heralded its covid-19 vaccine trials as a chance to boost participation among diverse populations, then it shuttered multiple sites that conducted them.
The popularity of at-home covid tests has amplified calls from public health researchers and diagnostic companies to make home testing similarly routine for sexually transmitted diseases. But FDA guidelines are lagging.
Californians will decide Nov. 8 whether to approve a statewide ban on the sale of flavored tobacco products, including menthol cigarettes. But the measure, known as Proposition 31, exempts hookah tobacco. Anti-smoking activists criticize the carve-out, calling it the latest example of businesses using identity politics to profit from a deadly product.
When Katie Couric announced she had breast cancer, she urged women to get a mammogram — and, if they have dense breasts, to get supplemental screening by ultrasound. But medical experts point out that ultrasound and other auxiliary screenings haven’t been proven to do more than regular mammography in reducing mortality.
The cheaper over-the-counter aids are for adults with mild to moderate hearing loss — a market of tens of millions of people, many of whom have until now been priced out because prescription devices can cost thousands of dollars.
Since pharmaceutical companies started funding their FDA drug applications 30 years ago, the agency’s reviews have gone much faster — perhaps too fast.
A cannabis product called delta-8 was made legal when the 2018 Farm Bill legalized hemp. But unlike its cousin CBD, delta-8 has psychoactive properties. And the FDA warns it has “serious health risks.” The agency has received more than 100 reports of bad reactions among people who consumed it.
Sales of formulas designed for toddlers increased in recent years, but health experts warn parents that, generally, once children reach their 1st birthday, they are fine with cow or plant milk and don’t need the expensive, high-calorie products. And doctors say toddler formula should not be given to infants.
California and New York would be the first states to require anyone under 18 to obtain prescriptions to purchase over-the-counter weight loss products, which some research has linked to eating disorders.
With fears of a winter surge looming, government agencies have authorized and encouraged vaccination with a newly formulated booster. But the science to support that decision remains inconclusive.
Lori McClintock, the wife of U.S. Rep. Tom McClintock of California, died after ingesting white mulberry leaf, according to the Sacramento County coroner. The plant is generally considered safe and is used in herbal remedies that claim to lower blood sugar, boost weight loss, and combat high cholesterol. Her death highlights the potential dangers of dietary supplements.
President Joe Biden has signed the Inflation Reduction Act and Congress is gone until after Labor Day. But the administration and lawmakers left lots of health policy achievements behind, including new rules to facilitate the sale of over-the-counter hearing aids and a potential reorganization of the Centers for Disease Control and Prevention. Anna Edney of Bloomberg News, Alice Miranda Ollstein of Politico, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KHN’s Julie Rovner to discuss these issues and more. Also, for extra credit, the panelists suggest their favorite health policy stories of the week they think you should read, too.
Paxlovid has eclipsed other available therapies for preventing life-threatening covid symptoms in high-risk patients. But even as doctors praise its effectiveness, many say they have unanswered questions about prescribing the drug and want more and better data about it.
Families affected by ultra-rare diseases are starting their own companies to speed the development of treatments for their kids, venturing into territory that traditional drugmakers deem too risky.
Existing drugs still treat most infections. But that has discouraged investment in new drugs that will be needed when — not if —the old ones fail.
A rapidly changing landscape for abortion has left patients, providers, employers, and lawmakers alike wondering what is and is not legal and what to do next. Meanwhile, Democrats in Congress have resumed negotiations on legislation to lower drug prices and, potentially, continue expanded insurance subsidies for the Affordable Care Act. Alice Miranda Ollstein of Politico, Tami Luhby of CNN, and Sandhya Raman of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
The FDA has approved a cannabis-derived drug, Epidiolex, to treat some forms of epilepsy. Now people who have other forms of the condition are using over-the-counter CBD products in hopes of taming their seizures. But doctors and patients worry about the unregulated world of CBD, in which product ingredients can be a mystery.
The drugmaker has the best-selling vaccine to prevent covid and the most effective drug to treat it. Its success has overshadowed the government’s covid-fighting strategy.
The Supreme Court’s decision overturning Roe v. Wade has created far more questions than it has answered about the continued legality and availability of abortion, as both abortion rights supporters and anti-abortion activists scramble to put their marks on policy. Meanwhile, Congress completes work on its gun bill and the FDA takes up the problem of the next covid-19 booster. Margot Sanger-Katz of The New York Times, Sarah Karlin-Smith of the Pink Sheet, and Victoria Knight of KHN join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KHN’s Angela Hart, who reported and wrote the latest KHN-NPR “Bill of the Month” episode about two identical eye surgeries with very different price tags.
The FDA is using its power to regulate tobacco products — ordering the vaping device Juul off the market and announcing its intention to lower the amount of nicotine in cigarettes and other products. Meanwhile, the Supreme Court rules on Medicare and kidney dialysis, and Congress makes progress on legislation surrounding guns and mental health. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KHN’s Noam N. Levey about the new KHN-NPR project on the growing impact of medical debt.
© 2026 KFF